- Sep 25, 2001
- 30,160
- 3,300
- 126
http://www.cnn.com/2013/06/13/politics/scotus-genes/index.html
The case involves Utah-based company Myriad Genetics, which was sued over its claim of patents relating to two types of biological material that it identified -- BCRA-1 and BCRA-2, whose mutations are linked to increased hereditary risk for breast and ovarian cancer.
Since Myriad owns the patent on breast cancer genes, it is the only company that can perform tests for potential abnormalities.
but a a synthetic version of the gene material may be patented
i agree w/the supreme court ruling. its like putting a patent on dog.
but dont understand what a synthetic version of the gene material is?
The case involves Utah-based company Myriad Genetics, which was sued over its claim of patents relating to two types of biological material that it identified -- BCRA-1 and BCRA-2, whose mutations are linked to increased hereditary risk for breast and ovarian cancer.
Since Myriad owns the patent on breast cancer genes, it is the only company that can perform tests for potential abnormalities.
but a a synthetic version of the gene material may be patented
i agree w/the supreme court ruling. its like putting a patent on dog.
but dont understand what a synthetic version of the gene material is?
Last edited: